China’s massive investment in biotech over the last couple of years has the potential to be a gamechanger for multi… https://t.co/DsbxEUtzRb
Pricing analytics: Next frontier for linking pricing and HTA data
As the pharmaceutical market landscape evolves and complex therapies make their way through the pipeline, it is becoming challenging for companies and payers to come to a consensus on the price-value debate. A lot of this evolution in pharma landscape has to do with legislation, and around new governance structures within the industry - a move from blockbuster to more targeted therapies. The profile of a customer has changed quite drastically over the last decade with the emergence of non-prescribing stakeholders into the mix.
Keeping in mind the new stakeholders more and more countries are implementing complex HTA driven frameworks to guide policy and pricing decisions. As the rationale goes, these newer decision support tools, in turn, help payers implement the efficient and effective use of health technologies so as to support innovation by identifying and rewarding high-value products while being cost-effective.
The players in the industry are facing increasing pressure to find newer markets for their therapies while undergoing an intensive scrutiny of existing drug prices on their portfolios. A most recent example of the price-value dilemma is evident in the story of the evaluation of Merck's Keytruda (pembrolizumab) for the treatment of untreated metastatic non-small cell lung cancer (NSCLC) - a major disease area due to higher incidence rates. UK's NICE rejected the drug in early 2017 for not being cost-effective for the newly diagnosed lung cancer patients only to reverse that decision in May so as to look at the data in more detail to make the final determination. Keytruda is already approved for skin cancer (melanoma) and classical Hodgkin's lymphoma and the trials have proven the drug to be very efficacious and safe for the new lung cancer patients.
Moreover, established and negotiated prices in one country eventually start impacting prices in other countries through the practice of reference pricing. In such a climate, it has become ever more important to understand the interwoven links between various data inputs that drive pricing.
Luckily for pharma with its entrenched data-capturing culture, there is a path forward. Analytics - especially around pricing - holds the key to convert raw price data into meaningful, measurable, and trackable insights that can guide various stakeholders towards decision points. The development of these analytical insight requires that different datasets be connected consistently while being able to capture real-time changes in the primary variables. The real magic and value - from pricing analytics perspective - is getting insight on the key relationships in the quickest time possible.
One such critical insight dimension is the understanding of how HTA decisions (and data points within those decisions) shape up the pricing of assets within a therapeutic group and vice-versa. Data visualisations and ensuing analytics that superimpose HTA data points with prices can open up new avenues for drawing meaningful insights on the downstream and upstream effects of the relationship between these two entities. The connectedness of data could open up new dimensions for further exploration.
It can allow teams to answer questions such as:
- Is there a causal link between price changes and HTA submissions for new indications or indication expansion?
- What impact do HTA outcomes have on prices within a therapeutic group?
- Is there an optimal way to design launch sequences that can generate maximum ROI on portfolio assets?
IHS Markit and Context Matters have for the first time combined these two diverse datasets under one platform so that companies can draw meaningful comparisons across countries, products, prices and HTA agencies. Through this new product - PriceCurrents - market access teams can develop narratives to support their pricing hypothesis. We announced the launch of this new product during this year's ISPOR in Boston.
Praful Mehta is a Senior Life Sciences Analyst for IHS Markit
Posted 16 June 2017
- Market access in China: An increasingly dynamic environment
- Pfizer and BioNTech's COVID-19 vaccine
- Mixed news on COVID19 vaccines: COVID-19 R&D tracker
- Innovation in Japan’s regenerative sector
- US drug prices could be drastically impacted by Most Favored Nation executive order
- Global healthcare spend to remain stable
- The pandemic pricing dilemma: A COVID-19 vaccine at-cost or for profit?
- US school re-opening decisions in a pandemic environment are complex – data can help
Pfizer and BioNTech's COVID-19 vaccine demonstrates over 90% efficacy as hope builds for an early end to the pandem… https://t.co/7oajgLXB0B
Register from the latest on the progression of the pandemic and the future that lies ahead of us from our Vice Pres… https://t.co/GiqhM1V318